Abstract:Despite accounting for >90% of the surface area of the GI tract, the small intestine has historically been responsible for <5% of all GI cancers. Over time, however, the incidence of small intestinal cancer has increased while other GI cancers (eg., colorectal, gastric, etc.) have decreased. To help elucidate the cause of this increase, we investigated histology-specific incidence and mortality trends in small intestinal cancer. We used SEER-9 data (covering ~10% of the US population) to identify 4 histological categories of small intestinal cancers (adenocarcinoma, neuroendocrine, lymphoma, and sarcoma/gastrointestinal stromal tumor [GIST]) to assess trends in incidence. Because death certificates do not include histology information, incidence-based mortality (IBM) was used to assess histology-specific mortality trends. From 1976 to 2016, 22,082 patients were diagnosed with one of four histological types of small intestinal cancer (ICD-O-3 codes C17.0-17.9). The overall incidence of these cancers more than doubled, from 12.1 to 27.9 per million (absolute increase 15.8; 95% CI: 14.3-17.3), largely because of a nearly 4-fold growth in neuroendocrine tumor incidence: from 3.7 to 14.6 per million (absolute increase 10.9; 95%CI: 10.0-11.8). The proportion of patients with localized disease increased from 14.7% of cases in 1976 to 38.9% of cases in 2014. There was little concomitant change in neuroendocrine mortality (from 1.4 to 2.2 per million, absolute increase 0.8; 95%CI: 0.4-1.2). The histologic distribution changed from 30% neuroendocrine histology in 1976 to 52% in 2016. Duodenal neuroendocrine tumors grew particularly rapidly from 0.1 to 4.2 per million (absolute increase 4.1; 95% CI, 3.7-4.5). Adenocarcinoma incidence rose slightly, but in tandem with mortality. Deaths attributed to small intestinal cancer on death certificates were virtually indistinguishable from adenocarcinoma IBM, suggesting that deaths attributed to small intestinal cancer were, in fact, predominantly due to adenocarcinoma. Both incidence and mortality of lymphoma initially rose before declining, similar to that for non-Hodgkin's lymphomas in general. Despite a small increase in GIST incidence, mortality decreased by 40% (from 1.0 to 0.6 per million). In summary, cancers of the small intestine are being diagnosed more frequently. There was little change in the occurrence of adenocarcinoma or the ability to treat the disease. Treatment advances, however, were apparent in GIST and lymphoma as evidenced by improvements in population-based mortality. Neuroendocrine tumor incidence increased rapidly and substantially while mortality was relatively stable, a pattern consistent with overdiagnosis and/or better diagnosis of symptomatic, low-lethality disease. Overdiagnosis appeared particularly likely in early stage and (more accessible) duodenal tumors. Citation Format: Haley J. Yao, Claire Sokas, H. Gilbert Welch. The role of overdiagnosis & better diagnosis of low-lethality disease in the rising incidence of cancer of the small intestine [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 5909.

Incidence, clinical management and prognosis of patients with small intestinal adenocarcinomas from 1999 through 2019: a nationwide Dutch cohort study

Abstract 5909: The role of overdiagnosis & better diagnosis of low-lethality disease in the rising incidence of cancer of the small intestine

Survival Outcomes and Surgical Intervention of Small Intestinal Neuroendocrine Tumors: a Population Based Retrospective Study

Risk and Prognostic Factors for Small Bowel Adenocarcinoma: A Multicenter Retrospective Observational Study in China

A Population-Based and Propensity Score-Matched Investigation of the Occurrence, Management, and Prognosis of Anal Mucinous Adenocarcinoma Patients

Current trend of worsening prognosis of prostate small cell carcinoma: A population-based study

Clinical features and the efficacy of adjuvant chemotherapy in resectable small bowel adenocarcinoma: a single-center, long-term analysis

Specific Survival Nomograms Based on SEER Database for Small Intestine Adenocarcinoma.

Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohort

Retrospective Analysis of 119 Small Bowel Adenocarcinoma in Chinese Patients

Clinical features, treatment, and prognosis of different histological types of primary small bowel adenocarcinoma: A propensity score matching analysis based on the SEER database

The incidence, treatment and survival of patients with rare types of rectal malignancies in the Netherlands: A population-based study between 1989 and 2018

A population-based study on intestinal and diffuse type adenocarcinoma of the oesophagus and stomach in the Netherlands between 1989 and 2015

Primary small intestinal malignant tumors: survival analysis of 48 postoperative patients.

Sinonasal mucosal melanoma in The Netherlands between 2001 and 2021: a clinical and epidemiological overview of 320 cases

Incidence, outcomes and prognostic factors during 25 years of treatment of chondrosarcomas

Efficacy of surgery and chemotherapy for stage IV small bowel adenocarcinoma: A population‐based analysis using Surveillance, Epidemiology, and End Result Program database

Primary Small-Bowel Malignancy: Update in Tumor Biology, Markers, and Management Strategies

A rare multiple primary sarcomatoid carcinoma (SCA) of small intestine harboring driver gene mutations: a case report and a literature review

Adjuvant chemotherapy for adenocarcinoma arising from intraductal papillary mucinous neoplasia: multicentre ADENO-IPMN study

Outlook for 615 Small Intestinal Neuroendocrine Tumor Patients: Recurrence Risk after Surgery and Disease-Specific Survival in Advanced Disease